A detailed history of Wells Fargo & Company transactions in Inmune Bio, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 4,222 shares of INMB stock, worth $20,941. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,222
Previous 3,963 6.54%
Holding current value
$20,941
Previous $34,000 35.29%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$4.86 - $9.86 $1,258 - $2,553
259 Added 6.54%
4,222 $22,000
Q2 2024

Aug 13, 2024

BUY
$7.15 - $11.84 $27,284 - $45,181
3,816 Added 2595.92%
3,963 $34,000
Q1 2024

May 10, 2024

BUY
$10.53 - $14.01 $21 - $28
2 Added 1.38%
147 $1,000
Q4 2023

Feb 09, 2024

SELL
$6.6 - $11.52 $14,645 - $25,562
-2,219 Reduced 93.87%
145 $1,000
Q3 2023

Nov 13, 2023

SELL
$6.61 - $10.9 $5,717 - $9,428
-865 Reduced 26.79%
2,364 $16,000
Q2 2023

Aug 15, 2023

SELL
$6.5 - $10.09 $988 - $1,533
-152 Reduced 4.5%
3,229 $29,000
Q1 2023

May 12, 2023

SELL
$6.01 - $10.18 $25,374 - $42,979
-4,222 Reduced 55.53%
3,381 $21,000
Q4 2022

Feb 13, 2023

SELL
$6.13 - $7.96 $31,109 - $40,397
-5,075 Reduced 40.03%
7,603 $48,000
Q3 2022

Nov 14, 2022

SELL
$6.04 - $10.44 $5,731 - $9,907
-949 Reduced 6.96%
12,678 $78,000
Q2 2022

Aug 12, 2022

SELL
$5.48 - $8.97 $3,227 - $5,283
-589 Reduced 4.14%
13,627 $121,000
Q1 2022

May 16, 2022

BUY
$6.42 - $11.39 $17,378 - $30,832
2,707 Added 23.52%
14,216 $120,000
Q4 2021

Feb 14, 2022

BUY
$9.97 - $20.38 $88,553 - $181,015
8,882 Added 338.1%
11,509 $118,000
Q3 2021

Nov 15, 2021

BUY
$14.13 - $27.85 $36,384 - $71,713
2,575 Added 4951.92%
2,627 $51,000
Q1 2021

May 13, 2021

BUY
$11.61 - $26.85 $139 - $322
12 Added 30.0%
52 $1,000
Q3 2020

Nov 05, 2020

BUY
$4.92 - $15.75 $83 - $267
17 Added 73.91%
40 $0
Q2 2020

Aug 13, 2020

BUY
$3.1 - $6.09 $3 - $6
1 Added 4.55%
23 $0
Q1 2020

May 14, 2020

BUY
$2.21 - $6.15 $48 - $135
22 New
22 $0

Others Institutions Holding INMB

About Inmune Bio, Inc.


  • Ticker INMB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,946,000
  • Market Cap $89M
  • Description
  • INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...
More about INMB
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.